BRISTOL-MYERS SQUIBB COMPANY Net Income (Loss) Available to Common Stockholders, Basic
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Net Income (Loss) Available to Common Stockholders, Basic of -$130.00 million for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-07-23.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2015-07-23
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) available to common stockholders, basic for the quarter ending 2015-06-30 was -$130.00M, a 139.04% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) available to common stockholders, basic for the quarter ending 2015-03-31 was $1.19B, a 26.57% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) available to common stockholders, basic for the quarter ending 2014-12-31 was $13.00M, a 98.21% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) available to common stockholders, basic for the quarter ending 2014-09-30 was $721.00M, a 4.19% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) available to common stockholders, basic for fiscal 2014 was $2.00B, a 21.81% decline from fiscal 2013.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) available to common stockholders, basic for fiscal 2013 was $2.56B, a 30.83% increase from fiscal 2012.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) available to common stockholders, basic for fiscal 2012 was $1.96B, a 47.07% decline from fiscal 2011.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) available to common stockholders, basic for fiscal 2011 was $3.70B, a 19.77% increase from fiscal 2010.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2015-06-30 | -$130.00M 10-Q · filed 2015-07-23 | $1.06B 10-Q · filed 2015-07-23 | $1.07B derived: sum of 3 quarters · filed 2015-07-23 | $1.79B derived: sum of 4 quarters · filed 2015-07-23 |
| 2015-03-31 | $1.19B 10-Q · filed 2015-04-28 | $1.20B derived: sum of 2 quarters · filed 2015-04-28 | $1.92B derived: sum of 3 quarters · filed 2015-04-28 | $2.25B derived: sum of 4 quarters · filed 2015-07-23 |
| 2014-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $734.00M derived: sum of 2 quarters · filed 2015-02-13 | $1.07B derived: sum of 3 quarters · filed 2015-07-23 | $2.00B 10-K · filed 2015-02-13 |
| 2014-09-30 | $721.00M 10-Q · filed 2014-10-24 | $1.05B derived: sum of 2 quarters · filed 2015-07-23 | $1.99B 10-Q · filed 2014-10-24 | $2.72B derived: sum of 4 quarters · filed 2015-07-23 |
| 2014-06-30 | $333.00M 10-Q · filed 2015-07-23 | $1.27B 10-Q · filed 2015-07-23 | $2.00B derived: sum of 3 quarters · filed 2015-07-23 | $2.69B derived: sum of 4 quarters · filed 2015-07-23 |
| 2014-03-31 | $937.00M 10-Q · filed 2015-04-28 | $1.66B derived: sum of 2 quarters · filed 2015-04-28 | $2.35B derived: sum of 3 quarters · filed 2015-04-28 | $2.89B derived: sum of 4 quarters · filed 2015-04-28 |
| 2013-12-31 | $726.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $1.42B derived: sum of 2 quarters · filed 2015-02-13 | $1.95B derived: sum of 3 quarters · filed 2015-02-13 | $2.56B 10-K · filed 2015-02-13 |
| 2013-09-30 | $692.00M 10-Q · filed 2014-10-24 | $1.23B derived: sum of 2 quarters · filed 2014-10-24 | $1.84B 10-Q · filed 2014-10-24 | $2.76B derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $536.00M 10-Q · filed 2014-07-24 | $1.15B 10-Q · filed 2014-07-24 | $2.07B derived: sum of 3 quarters · filed 2015-02-13 | $1.36B derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $609.00M 10-Q · filed 2014-04-29 | $1.53B derived: sum of 2 quarters · filed 2015-02-13 | $823.00M derived: sum of 3 quarters · filed 2015-02-13 | $1.47B derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $925.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $214.00M derived: sum of 2 quarters · filed 2015-02-13 | $859.00M derived: sum of 3 quarters · filed 2015-02-13 | $1.96B 10-K · filed 2015-02-13 |
| 2012-09-30 | -$711.00M 10-Q · filed 2013-10-23 | -$66.00M derived: sum of 2 quarters · filed 2013-10-23 | $1.03B 10-Q · filed 2013-10-23 | $1.88B derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-06-30 | $645.00M 10-Q · filed 2013-07-25 | $1.74B 10-Q · filed 2013-07-25 | $2.60B derived: sum of 3 quarters · filed 2014-02-14 | $3.56B derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-03-31 | $1.10B 10-Q · filed 2013-04-25 | $1.95B derived: sum of 2 quarters · filed 2014-02-14 | $2.92B derived: sum of 3 quarters · filed 2014-02-14 | $3.82B derived: sum of 4 quarters · filed 2014-02-14 |
| 2011-12-31 | $850.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $1.82B derived: sum of 2 quarters · filed 2014-02-14 | $2.72B derived: sum of 3 quarters · filed 2014-02-14 | $3.70B 10-K · filed 2014-02-14 |
| 2011-09-30 | $967.00M 10-Q · filed 2012-10-24 | $1.87B derived: sum of 2 quarters · filed 2012-10-24 | $2.85B 10-Q · filed 2012-10-24 | $3.33B derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-06-30 | $900.00M 10-Q · filed 2012-07-25 | $1.88B 10-Q · filed 2012-07-25 | $2.37B derived: sum of 3 quarters · filed 2013-02-15 | $3.31B derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-03-31 | $984.00M 10-Q · filed 2012-04-26 | $1.47B derived: sum of 2 quarters · filed 2013-02-15 | $2.41B derived: sum of 3 quarters · filed 2013-02-15 | $3.33B derived: sum of 4 quarters · filed 2013-02-15 |
| 2010-12-31 | $482.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $1.43B derived: sum of 2 quarters · filed 2013-02-15 | $2.35B derived: sum of 3 quarters · filed 2013-02-15 | $3.09B 10-K · filed 2013-02-15 |
| 2010-09-30 | $945.00M 10-Q · filed 2011-10-27 | $1.87B derived: sum of 2 quarters · filed 2011-10-27 | $2.61B 10-Q · filed 2011-10-27 | |
| 2010-06-30 | $924.00M 10-Q · filed 2011-07-28 | $1.66B 10-Q · filed 2011-07-28 | ||
| 2010-03-31 | $740.00M 10-Q · filed 2011-04-28 | |||
| 2009-12-31 | $10.55B 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |